Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer

Abstract

BackgroundLymph node metastasis of triple-negative breast cancer (TNBC) is essential in treatment strategy formulation. This study aimed to build a nomogram that predicts lymph node metastasis in patients with TNBC.Materials and MethodsA total of 28,966 TNBC patients diagnosed from 2010 to 2017 in the Surveillance, Epidemiology and End Results (SEER) database were enrolled, and randomized 1:1 into the training and validation sets, respectively. Univariate and multivariate logistic regression analysis were applied to identify the predictive factors, which composed the nomogram. The receiver operating characteristic curves showed the efficacy of the nomogram.ResultMultivariate logistic regression analyses revealed that age, race, tumor size, tumor primary site, and pathological grade were independent predictive factors of lymph node status. Integrating these independent predictive factors, a nomogram was successfully developed for predicting lymph node status, and further validated in the validation set. The areas under the receiver operating characteristic curves of the nomogram in the training and validation sets were 0.684 and 0.689 respectively, showing a satisfactory performance.ConclusionWe constructed a nomogram to predict the lymph node status in TNBC patients. After further validation in additional large cohorts, the nomogram developed here would do better in predicting, providing more information for staging and treatment, and enabling tailored treatment in TNBC patients.

Identifying Clinicopathological Risk Factors of the Regional Lymph Node Metastasis in Patients with T1-2 Mucinous Breast Cancer: A Population-Based Study

“…Referencing similar work on predicting LNM in patients with different subtypes of breast cancer, our study took it a step further. For instance, while the study population in one nomogram constructed by Cui et al [15] for predicting the LNM in TNBC patients was larger than ours, the C-index of the training set was only 0.684. Besides the nomogram for predicting the LNM in T 1 breast cancer developed by Zhao et al [20], the C-index of the training group and validation group achieved 0.733 and 0.741, respectively, which were still weaker than ours.…”

“…During the past years, a lot of research has been done on determining the risk factors for lymph node involvement and survival in patients with different subtypes of breast cancer or coexisting with distant metastasis at initial diagnosis [13,[15][16][17][18][19]. As IDC and invasive lobular carcinoma (ILC) accounted for the vast majority of cases, the clinicopathological characteristics of these two types of breast cancer were the main object of intensive research.…”

“…As IDC and invasive lobular carcinoma (ILC) accounted for the vast majority of cases, the clinicopathological characteristics of these two types of breast cancer were the main object of intensive research. For instance, Wang et al established a nomogram for predicting the prognosis of female patients with breast cancer and bone metastasis at presentation [ 19 ] and Cui et al [ 15 ] established a nomogram for predicting the LNM in TNBC patients. On the contrary, PMBC, as a rare histologic type of mammary neoplasm, accounting for 1–4% of all breast cancers, has rarely been investigated and usually was classified as “others” group in several studies [ 14 , 16 , 19 , 20 ].…”

Prognostic Nomogram for Postoperative Patients With Gastroesophageal Junction Cancer of No Distant Metastasis

“…In the process of external verification of the nomogram, we used multivariate Cox regression analysis to verify the results of the training cohort, and got the C index and calibration curve. Then the training and the verification cohorts were scored and divided into high-and low-risk groups via the Youden's index (12). Kaplan-Meier survival analysis was applied to detect the effect of high-and low-risk groups on the prognosis of patients with GEJ cancer without distant metastasis.…”

Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer

“…Breast cancer is the world's most prevalent malignant disease [4]. Triple-negative breast cancer (TNBC) is one of the subtypes of breast cancer that, in recent years, has not been identified as the estrogen receptor, progesterone receptor, or human growth factor 2 [5]. TNBC has severe invasiveness, high malignancy, and short relapse-free survival, representing the critical role of early diagnosis and precise progression [6].…”